Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium

Award Number: UM1AI179699
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/26/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium - Project Summary The long duration and multidrug nature of tuberculosis (TB) treatment regimens pose obstacles to treatment completion for patients and providers, but also challenge research efforts to develop new and improved regi- mens. Without a validated early biomarker able to discriminate regimens with different curative potential, the field depends heavily on preclinical models. However, TB regimen development has been slow, often hindered and misled by poor preclinical-to-clinical translation. Animal models and pharmacometric modeling played key roles in developing groundbreaking novel regimens capable of shorting treatment durations for drug-susceptible and multidrug-resistant TB to 4 and 6 months, respectively. However, these tools are still not utilized to their full potential. Recent successes in TB drug discovery have produced additional clinical and preclinical drug candi- dates, which have revealed a new challenge: with many possible combinations, how to prioritize multidrug regi- mens to test in resource-intensive clinical trials? The most efficient “critical path” of preclinical experiments and modeling to follow to identifying and optimizing the best regimens for advancement to clinical trials remains uncertain. The proposed project will establish a comprehensive, collaborative, multidisciplinary consortium of scientific leaders, drug developers and other stakeholders to develop and pursue a preclinical and translational research agenda to identify novel regimens with the greatest potential for clinical success in adults and children with TB. The overarching hypothesis is that integration and analysis of specific preclinical and early clinical data using validated models and tools will enable data-driven clinical trial simulations that yield quantitative predictions of Phase 2 and Phase 3 trial endpoints useful to identify and rank regimens with the highest probability of clinical success in patients across the age and disease spectrum of pulmonary TB. Initial efforts will be aimed at refining and validating preclinical in vivo (BALB/c and C3HeB/FeJ mouse) and in vitro models and translational tools by leveraging the largest data warehouse on TB drugs and regimens ever assembled, with data spanning from early preclinical stages to Phase 3 clinical trials, for both back translation and forward prediction approaches to validation. The overall goal is to develop a fully data- and knowledge-driven approach to evaluate, prioritize and optimize novel drug regimens for clinical trials requiring only preclinical and early clinical trial data. In addition to endpoints based on bacterial burden and relapse (in mice), the RS ratio, a new portable biomarker of bacterial “health”, will be evaluated as a complementary pharmacodynamic (PD) biomarker to increase efficiency and predictive accuracy of preclinical studies. The expected outcomes are novel methodologies of combining pre- clinical and early clinical data, a defined set of critical path experiments with predictive value, and a framework for model-informed decision-making based on quantitative predictions of clinical outcomes for emerging regi- mens prior to initiation of phase 2/3 trials. The predictions will be used to rank order candidate regimens for advancement to clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $7,200,000 )
2026	2026	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	3	1/30/2026	NON-COMPETING CONTINUATION	$7,200,000
														Subtotal = $7,200,000

Issue Date FY: 2025 ( Subtotal = $7,200,000 )
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	001	2	8/20/2025	NON-COMPETING CONTINUATION	$0
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	2	7/10/2025	NON-COMPETING CONTINUATION	$7,200,000
														Subtotal = $7,200,000

Issue Date FY: 2024 ( Subtotal = $7,199,999 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	001	1	8/16/2024	NEW	$1,039,999
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	3/26/2024	NEW	$6,160,000
														Subtotal = $7,199,999

Grand Total All Awards = $21,599,999

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium

Award Number: UM1AI179699

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/26/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer